Question Bank › Sequential re-rating

Sequential re-rating

Sequential re-rating: management describes the same offering landing bigger the second and third time around

Calls Tested
498
Answered YES
7
Hit Rate
1.4%
rare by design

Kamada Ltd. (KMDA) — this company's answers

NO on the Q2 2023 call 2023-08-16 B+
The model's full reasoning — Q2 2023 call → NOWe need to determine if management describes successive engagements of the same kind coming in at progressively larger size. The question asks: does management convey that deals, orders, contracts, projects, customers, sites, or programs it is landing NOW are individually bigger, broader, or longer than the ones it was landing for the same offering not long ago, so that each new instance of essentially the same business is worth more to the company than the last? We need to look for evidence in the transcript. The transcript covers Kamada's Q2 2023 earnings call. Management discusses various products: KEDRAB, CYTOGAM, HEPAGAMB, VARIZIG, WINRHO, and the InnovAATe trial. Also mentions plasma collection centers. Key points: - KEDRAB sales increased significantly. They mention "significant increase in demand for the product in the U.S." and "anticipate even further momentum in the second half of the year." But is that about unit size? They talk about increased sales, but not about the size of individual orders or contracts. They mention that Kedrion extended the distribution agreement through March 2026. That's a longer duration, but is that an escalation of unit size? The agreement extension is about duration, not necessarily about larger orders per instance. They also mention "active discussion with Kedrion to potentially further expand the scope of our collaboration." That suggests potential broader scope, but it's not yet realized. Also, they talk about the U.S. market being $150 million annually, and they are taking market share. But that's about volume, not about individual deal size. - For the IgG products, they mention "continued growth of the new IgG product sales in the U.S., fueled by the ongoing marketing efforts as well as the expansion of ex-U.S. sales." Again, that's about volume. - For InnovAATe trial, they mention enrollment ramping, but that's a clinical trial, not a commercial deal. - For plasma collection, they mention opening a second center in Houston in early 2024. That's expansion of sites, but not necessarily that each site is bigger. - They also mention the $60 million financing from FIMI, which is a strategic investment, not a business deal of the same kind. The question specifically asks about "successive engagements of the same kind" coming in at progressively larger size.

← Back to the full KMDA analysis

Show the exact prompt the model was given
Using ONLY the supplied earnings call transcript and no outside information: On this call, does management describe that the company's SUCCESSIVE ENGAGEMENTS OF THE SAME KIND ARE COMING IN AT PROGRESSIVELY LARGER SIZE — that is, does management convey that the deals, orders, contracts, projects, customers, sites, or programs it is landing NOW are individually bigger, broader, or longer than the ones it was landing for the same offering not long ago, so that each new instance of essentially the same business is worth more to the company than the last? Answer YES when management's own words convey, in whatever form fits the business, ONE coherent phenomenon as a present-tense reality: the unit size of the company's own repeatable business is escalating. Any genuine expression of this counts, and the form varies widely across industries. For example — management noting that the average size of new orders, contracts, or deals has stepped up versus what the company used to sign; that its newest customers are starting at a level its early customers took years to reach, or are entering at broader scope from the outset; that where it once sold a single unit, department, site, or product, the same type of buyer now commits to many at once; that follow-on commitments from the same counterparties are arriving at multiples of the initial ones; that the projects, programs, or engagements it is now being awarded are individually larger or longer-dated than its historical norm; that initial commitments increasingly arrive as full deployments rather than as trials; or that the largest single piece of business in the company's history was just signed and management presents it as part of an upward drift in deal size rather than an isolated event. Three things should come through in management's own voice. First, A COMPARISON AGAINST THE COMPANY'S OWN RECENT PAST — management contrasts the size or scope of what it is landing now with what it was landing before for substantially the same offering, so the point is escalation of unit size, not merely more units or a good quarter. Second, ALREADY REAL AND RECURRING — the larger instances are things actually signed, ordered, awarded, or begun in the recent period, and management conveys a pattern rather than one exceptional event; a single record deal counts only if management frames it as part of an upward drift in the size of what the company is winning. Third, EARLY — management conveys, directly or plainly in substance, that this escalation is recent enough that the reported results still largely reflect the smaller-instance era, and that further instances at the new, larger size are already forming, in negotiation, or expected to keep arriving. Answer NO if management simply reports strong demand, more customers, higher revenue, or a good quarter without conveying that the individual size of what it lands has grown versus its own past. NO if the growth described comes purely from volume — more of the same-sized business — or from price increases on unchanged scope. NO if larger deals are only hoped for, targeted, sitting in a pipeline, or described as an ambition to move upmarket. NO if the only evidence is one outsized transaction that management itself treats as exceptional or non-repeating. NO if large engagements have always been the ordinary unit of this company's business and nothing about their size has changed. NO if management is chiefly describing deal sizes shrinking, scopes being cut, customers downsizing commitments, or contracts being renegotiated smaller. NO if the escalation is already mature and fully reflected in current results, with nothing further ahead. NO if the idea appears only in an analyst's question or characterization that management does not itself affirm. Use only the supplied transcript. Answer only YES or NO.

Companies that answered YES

TickerCompanyCallDateCall grade
ASO Academy Sports and Outdoors, Inc. Q1 2024 2024-06-11 C+
AKYA Akoya Biosciences, Inc. Q2 2023 2023-08-07 C+
SPT Sprout Social, Inc. Q2 2023 2023-08-04 B+
SGRY Surgery Partners, Inc. Q2 2022 2022-08-02 B+
CYBR CyberArk Software Ltd. Q3 2021 2021-11-04 B+
ASAN Asana, Inc. Q2 2022 2021-09-01 B+
OWL Blue Owl Capital Inc. Q2 2021 2021-08-10 B+

How the model reasoned

AKYA · Q2 2023 → YESThe question is: Does management describe that the company's SUCCESSIVE ENGAGEMENTS OF THE SAME KIND ARE COMING IN AT PROGRESSIVELY LARGER SIZE? YES The transcript shows management describing a clear pattern of escalating project sizes in the translational/clinical space. Brian notes a migration from exploratory studies (reasonable size) to larger retrospective studies and even larger retrospective-prospective ongoing clinical studies, with projects moving "further and further downstream.
ASAN · Q2 2022 → YESThe question is: Does management describe that the company's SUCCESSIVE ENGAGEMENTS OF THE SAME KIND ARE COMING IN AT PROGRESSIVELY LARGER SIZE? YES Management describes exactly this pattern. Dustin notes the company is “closing larger deals and expanding seats across departments and geographies quickly in large organizations,” and that the growth in the >$50k cohort “reflected an acceleration in our largest enterprise customers.
SGRY · Q2 2022 → YESThe question is: Does management describe that the company's SUCCESSIVE ENGAGEMENTS OF THE SAME KIND ARE COMING IN AT PROGRESSIVELY LARGER SIZE? YES The transcript shows management describing exactly this pattern for physician recruiting cohorts. Wayne notes that the 2022 cohorts are “no exception to this trend, bringing more cases with a higher overall net revenue per case than our 2021 cohorts did in the same period last year.

More from the question bank

Answers go deeper than the scriptFresh evidence outrunning the reported numbeSold before it existsCustomers coming back on their ownPromise already turning into factThe open question just closedAll questions →
Not investment advice. Artul.ai publishes AI-generated earnings-call quality grades and expected-volatility estimates — never buy or sell recommendations. We tested over 1,600 predictive hypotheses against 165,000 transcripts; the honest result, including what failed, is documented in our methodology.